Sales of Novo Nordisk's Victoza drop in US
Diabetes drug Victoza has had lower sales this year than during the same period last year.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
Novo Nordisk's best selling drug, diabetes medicine Victoza, has lost momentum in the US over the past few weeks.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly acquires biotech firm in new insulin venture
For subscribers
